Physician profile
Christopher Kyle Totten
NPI 1235835224
$1,885.08
in general payments reported to CMS, 2019-2025
10 companies · $22.45 in 2025
The $22.45 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,766 · 2024: $97.08 · 2025: $22.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.08 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.98 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $569.57 | 2023 | Uzedy, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $198.28 | 2023 | Invega Sustenna, Invega Trinza, Invega |
| Otsuka America Pharmaceutical, INC. | $161.28 | 2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $141.65 | 2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.28 | 2023-2024 | Caplyta |
| Indivior INC. | $43.91 | 2023 | Perseris |
| Alkermes, INC. | $41.04 | 2023 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $34.64 | 2023 | Fanapt, Hetlioz |
| Corium, LLC | $22.45 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Totten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.